GlaxoSmithKline plc Stock LIQUIDNET SYSTEMS
Stocks
GSK
GB0009252882
Pharmaceuticals
OTC Markets Traded|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| - EUR | -.--% |
|
-0.40% | - |
| 19/06 | Moderna Secures Favorable FDA Panel Recommendation for mRNA Flu Vaccine |  |
| 18/06 | The Gulf Gives, the Fed Takes | |
| Market Cap | 76.77B 101B 88.4B 81.53B 143B 9,560B 144B 971B 376B 4,706B 380B 372B 16,351B | P/E 2026 * |
12.3x | P/E 2027 * | 11.4x |
|---|---|---|---|---|---|
| Enterprise Value | 91.02B 120B 105B 96.67B 170B 11,335B 171B 1,151B 446B 5,580B 451B 441B 19,387B | EV / Sales 2026 * |
2.69x | EV / Sales 2027 * | 2.48x |
| Free-Float |
92.29% | Yield 2026 * |
3.64% | Yield 2027 * | 3.81% |
Last Transcript: GlaxoSmithKline plc
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | - | 01/01/2026 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 01/05/2023 |
| Chief Tech/Sci/R&D Officer | - | 01/12/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | - | 06/05/2026 |
Hal Barron
BRD | Director/Board Member | 64 | 01/01/2018 |
Jonathan Symonds
CHM | Chairman | 68 | 01/09/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -0.40% | - | - | 105B | |
| -1.21% | -3.33% | +38.84% | +145.38% | 992B | |
| -2.48% | -4.23% | +49.88% | +39.07% | 564B | |
| -2.14% | -3.76% | +16.72% | +56.15% | 391B | |
| -1.18% | +0.68% | +24.66% | +16.53% | 330B | |
| -2.36% | -2.30% | +23.37% | +11.59% | 280B | |
| -2.45% | -0.84% | +23.51% | +30.06% | 279B | |
| -1.91% | -1.06% | -42.60% | -49.25% | 196B | |
| -1.19% | -0.04% | +16.39% | +47.00% | 184B | |
| -1.35% | +1.88% | +14.59% | +56.94% | 156B | |
| Average | -0.76% | +0.41% | +18.37% | +39.27% | 374.58B | |
| Weighted average by Cap. | -0.51% | -0.49% | +27.10% | +63.21% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.78B 44.61B 38.91B 35.88B 63.06B 4,207B 63.56B 427B 165B 2,071B 167B 164B 7,196B | 35.48B 46.84B 40.86B 37.68B 66.22B 4,418B 66.75B 449B 174B 2,175B 176B 172B 7,557B |
| Net income | 6.27B 8.27B 7.22B 6.66B 11.7B 780B 11.79B 79.25B 30.68B 384B 31.03B 30.39B 1,335B | 6.67B 8.81B 7.68B 7.08B 12.45B 831B 12.55B 84.34B 32.66B 409B 33.02B 32.34B 1,421B |
| Net Debt | 14.25B 18.82B 16.41B 15.14B 26.6B 1,775B 26.81B 180B 69.79B 874B 70.57B 69.12B 3,036B | 11.19B 14.77B 12.89B 11.88B 20.88B 1,393B 21.05B 142B 54.79B 686B 55.4B 54.26B 2,383B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
- GSK Stock
Select your edition
All financial news and data tailored to specific country editions
